LCM
OTLK icon

Landscape Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Landscape Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-82
Closed -$35K – 427
2017
Q1 		$35K Buy
+82
New +$40.8K ﹤0.01% 495

Other funds holding OTLK

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Landscape Capital Management's OTLK Position: Q2 2017 in Review

Landscape Capital Management sold out of Outlook Therapeutics (OTLK) in Q2 2017, closing a stake of 82 shares — an estimated $35K sold.

Landscape Capital Management first reported a position in OTLK in Q1 2017 and held it in 1 quarter. The position peaked at $35K in Q1 2017. 16 funds tracked by Wall St. Rank hold OTLK as of Q2 2017.

  • Landscape Capital Management reported no remaining Outlook Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Landscape Capital Management sold 82 Outlook Therapeutics shares in Q2 2017, an estimated $35K.
  • Landscape Capital Management first reported a position in Outlook Therapeutics in Q1 2017 and held it in 1 quarter.
  • Landscape Capital Management's Outlook Therapeutics position peaked at $35K in Q1 2017.
  • 16 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2017.

Based on Landscape Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.